Millions of infertile women will soon get the biggest baby boost in a generation from preimplantation genetic diagnosis (PGD), which identifies their healthiest embryos at in vitro fertilization (IVF) clinics for transfer. Studies show that PGD doubles the chances of a woman in her mid-30s to early-40s of delivering a single, healthy baby per IVF attempt to nearly 60 percent. The current U.S. average is 31 percent. To capitalize on this emerging market, Illumina (ILMN) in September acquired Cambridge, U.K.-based BlueGnome Ltd., for an undisclosed amount. The privately held BlueGnome has developed technologies needed for a 24-hour PGD test.
Here's the surprising story: sandiegobiotechnology.com |
